Quanterix Corp (QTRX) is a life science company committed to advancing precision health. Recognized as a leader in the development and commercialization of ultra-sensitive, innovative digital immunoassay platforms that specifically target the detection of protein biomarkers, the company is enabling better insights into disease using non-invasive detection of key biomarkers in blood.
Founded in 2007 and based in Billerica Massachusetts, Quanterix's mission is to deliver a groundbreaking technology, Simoa, which stands for Single Molecule Array technology. Simoa was developed at Tufts University by Dr. David Walt, who co-founded Illumina, and has the potential to transform the management and diagnosis of a broad range of diseases. Significantly, Quanterix offers the potential to detect diseases much earlier than has traditionally been possible.
Quanterix's technology is based on the idea that valuable medical intelligence about a patient's health can be mined from a single drop of blood, and the capture and analysis of these biomarkers can allow for precise health evaluations. These evaluations can identify disease at its earliest stages, predict health trajectory, and monitor progression and treatment effectiveness.
The company's innovative products and services enable researchers in academic, clinical and pharmaceutical organizations to advance their research in understanding the role of proteins in various conditions, including neurology, oncology, cardiology, inflammation, and infectious disease.
Quanterix has a portfolio of products including the Simoa HD-1 Analyzer, the Simoa SR-X Ultrsensitive Benchtop Analyzer, and the SP-X Imaging and Analysis system. Each technology platform facilitates different types of assays.
In the financial markets, Quanterix Corp is listed on NASDAQ under the symbol QTRX. With a continued effort to lead through scientific innovation, Quanterix is poised to continue delivering on its ambitious mission of revolutionizing the way in which healthcare is provided, moving from a reactive, symptomatic approach to a proactive, preventative approach.
From a corporate culture perspective, Quanterix is founded on principles of integrity, collaboration, passion, and innovation. They continuously maintain a commitment to fostering a diverse and inclusive workforce where every employee is valued and recognized for their contributions towards achieving the company's mission.
Through their ground-breaking technology, Quanterix is redefining the world of precision health, making significant strides in a rapidly evolving field and creating a new frontier of healthcare solutions and diagnostics.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Quanterix Corporation (QTRX) filed its Q3 2026 10-Q report, revealing $46.9 million in impairment and restructuring costs for the nine-month period, largely due to writing down goodwill from the Akoya acquisition and an IPR&D asset. While nine-month costs increased, Q3 2026 impairment costs significantly decreased year-over-year. The report also highlighted increases in cost of product and service revenue, partly due to the Akoya business inclusion, and 47.5 million shares outstanding as of November 2, 2026.
Quanterix Corporation (QTRX) filed an SEC Form 8-K detailing its financial results. The company reported Q3 revenue of $35.0 million, a 13% year-over-year decrease but a 6% quarter-over-quarter increase, and narrowed its FY26 revenue guidance to $142M-$146M, with $81M cash on hand. The filing, published on November 9, 2026, also included information on historical stock performance following previous headlines.
Quanterix Corporation (QTRX) filed an SEC Form 8-K reporting its third-quarter 2026 financial results. The company posted revenue of $35.0 million, a 6.3% increase quarter-over-quarter but a 13% decrease year-over-year. Quanterix also narrowed its full-year 2026 revenue guidance to $142 million to $146 million and updated its year-end cash balance outlook to $70 million.